Clinical Trial Search

Primary: Percentage of Patients Free From Breast Cancer — 89.1; 93.1 percentage of participants event-free

Primary: Percentage Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C) — -18.7; -39.8; -47.2; -54.6 Percentage Change — p=<0.001

Primary: Frequency of Subjects With a Deterioration of Hearing Threshold at Day 35 (Air Conduction) — 10; 2; 2 Number subject affected — p=0.128

Primary: Percent of Participants Demonstrating 20% or More Increase in Total Kidney Volume — 69; 88 percentage of participants — p=0.03

Primary: Change in HbA1c From Baseline — -1.21; -1.64; -0.83 percentage — p=<0.0001

Primary: Number of Urge Urinary Incontinence (UUI) Episodes — -3.25; -3.89 UUI episodes

Primary: Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment. — 5.5; 8.3; 6.0 months — p=0.0183

Primary: Change From Baseline in HbA1c at Week 24 — -0.69; 0.14 Percent — p=<0.001

Primary: The Number of Participants With Excellent Reduction in Bleeding When Given FACTOR X as Routine Prophylaxis Over 6 Months — 9 Participants

Primary: Change From Baseline in HbA1c at Week 24 — -0.84; -0.07 Percent — p=<0.001

Primary: Time to First On-study Skeletal Related Event — 730.0; 695.0 days — p=0.010

Primary: Measures of Safety and Tolerability: Nature and Frequency of Adverse Events (AEs) — 188; 109; 8; 54 participants

Primary: Number of Seroconverted (SCR) Subjects for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California/7/2009 (H1N1) Virus Strain — 60; 44 Participants

Primary: Time-weighted Sum of Pain Intensity Difference Scores on 11-Point Numerical Scale From 0 to 24 Hours Post-dose (SPID11 [0-24]) — -8.13; 64.76 units on a Scale — p=<0.001

Primary: Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies — 14.4; 84.1; 107; 44.3 Titers (1/dilutions)